Pharming Group announces presentation of new leniolisib data at 2022 ASH Annual MeetingPRNewsWire • 11/23/22
Can Pharming Group N.V. Sponsored ADR (PHAR) Run Higher on Rising Earnings Estimates?Zacks Investment Research • 11/08/22
Pharming Announces European Medicines Agency (EMA) Validates its Marketing Authorisation Application under Accelerated Assessment for leniolisibPRNewsWire • 10/28/22
Pharming submits a Marketing Authorisation Application to the European Medicines Agency for LeniolisibPRNewsWire • 10/11/22
Pharming Announces US FDA Acceptance for Priority Review of its New Drug Application for LeniolisibPRNewsWire • 09/28/22
CEO of Pharming to present at H.C. Wainwright 24th Annual Global Investment ConferencePRNewsWire • 09/07/22
Pharming Group N.V.'s (PHGUF) CEO Sijmen de Vries on First Half 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/06/22
Pharming Group Receives Accelerated Assessment in Europe for leniolisib for the Treatment of Rare Immunodeficiency, APDSPRNewsWire • 08/01/22
Pharming Group N.V. (PHGUF) CEO Sijmen de Vries on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/15/22
Pharming receives agreement of Paediatric Investigation Plan and Promising Innovative Medicine designation for leniolisib from UK MHRAPRNewsWire • 04/26/22
Pharming Announces Positive Data from Phase II/III Leniolisib Trial Presented at Clinical Immunology Society 2022 Annual MeetingPRNewsWire • 04/01/22
Pharming Group N.V. (PHGUF) CEO Sijmen Vries on Full Year 2021 Results - Earnings Call TranscriptSeeking Alpha • 03/17/22